Physician profile
Khai DO
NPI 1396939526
$6,994.71
in general payments reported to CMS, 2019-2025
34 companies · $2,371 in 2025
The $2,371 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $105 · 2021: $440 · 2022: $1,118 · 2023: $1,416 · 2024: $1,440 · 2025: $2,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,226.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,252.30 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $787.18 | 2020-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $725.93 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $703.08 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $511.52 | 2019-2025 | Repatha, Otezla, Repatha |
| Axsome Therapeutics, INC. | $448.58 | 2024-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $402.47 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.38 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $239.27 | 2019-2025 | Kisunla, Mounjaro, Zepbound |
| Esperion Therapeutics, INC. | $200.82 | 2022-2024 | Nexletol |
| Pfizer INC. | $199.71 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $133.54 | 2021-2023 | |
| Scilex Pharmaceuticals INC. | $118.51 | 2022-2023 | Ztlido |
| Xeris Pharmaceuticals, INC. | $105.43 | 2022-2024 | Gvoke Hypopen |
| Amarin Pharma, INC. | $89.02 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $87.64 | 2022 | |
| Redhill Biopharma INC. | $84.48 | 2021-2023 | Movantik, Aemcolo, Talicia |
| Horizon Therapeutics Plc | $78.84 | 2021-2022 | |
| Ardelyx, INC. | $71.02 | 2024-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.35 | 2023-2024 | Xifaxan |
| Biogen, INC. | $47.07 | 2020-2021 | |
| Astellas Pharma US INC | $43.38 | 2024 | Veozah |
| Allergan, INC. | $36.83 | 2019 | |
| Hologic Sales and Service, LLC | $33.68 | 2023-2024 | Aptima, Thinprep 2000 Processor |
| Glaxosmithkline, LLC. | $27.30 | 2025 | Trelegy Ellipta |
| Genentech USA, INC. | $24.87 | 2020 | |
| Lundbeck LLC | $24.07 | 2023 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $22.73 | 2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $21.54 | 2021 | |
| Aimmune Therapeutics, INC. | $20.20 | 2025 | Zenpep |
| Exact Sciences Corporation | $18.78 | 2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $16.79 | 2019 | |
| Sumitomo Pharma America, INC. | $15.73 | 2025 | Gemtesa |
| Dexcom, INC. | $13.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khai DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.